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Background: Polyetheretherketone (PEEK) cages have been widely used in the treatment of lumbar degenerative
disc disorders, and show good clinical results. Still, complications such as subsidence and migration of the cage are
frequently seen. A lack of osteointegration and fibrous tissues surrounding PEEK cages are held responsible. Ceramic
implants made of silicon nitride show better biocompatible and osteoconductive qualities, and therefore are expected to
lower complication rates and allow for better fusion.
Purpose of this study is to show that fusion with the silicon nitride cage produces non-inferior results in outcome of the
Roland Morris Disability Questionnaire at all follow-up time points as compared to the same procedure with PEEK cages.
Methods/Design: This study is designed as a double blind multi-center randomized controlled trial with repeated
measures analysis. 100 patients (18–75 years) presenting with symptomatic lumbar degenerative disorders unresponsive
to at least 6 months of conservative treatment are included. Patients will be randomly assigned to a PEEK cage or a silicon
nitride cage, and will undergo a transforaminal lumbar interbody fusion with pedicle screw fixation. Primary outcome
measure is the functional improvement measured by the Roland Morris Disability Questionnaire. Secondary outcome
parameters are the VAS leg, VAS back, SF-36, Likert scale, neurological outcome and radiographic assessment of fusion.
After 1 year the fusion rate will be measured by radiograms and CT. Follow-up will be continued for 2 years. Patients and
clinical observers who will perform the follow-up visits will be blinded for type of cage used during follow-up. Analyses of
radiograms and CT will be performed independently by two experienced radiologists.
Discussion: In this study a PEEK cage will be compared with a silicon nitride cage in the treatment of symptomatic
degenerative lumbar disc disorders. To our knowledge, this is the first randomized controlled trial in which the silicon
nitride cage is compared with the PEEK cage in patients with symptomatic degenerative lumbar disc disorders.
Trial registration: NCT01557829
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Chronic low back pain is an important reason for patients
to visit general practitioners. In Europe, estimates of life-
time prevalence of chronic low back pain range from ap-
proximately 60–90% [1]. It is one of the leading causes of
activity limitation in adults and results in high socio-
economic costs and loss of quality of life [2]. The exact
cause of chronic low back pain is often unknown, but de-
generative disorders of the intervertebral disc are held re-
sponsible [3]. The pain can be eliminated by stabilizing the
degenerative segment, for example as seen in the successful
treatment of degenerative joints with an arthrodesis [4,5].
Spinal fusion is commonly used for stabilizing degenerative
and isthmic spondylolisthesis and severe, painful disc
degeneration.
In a spinal fusion, two or more vertebrae are fused after
a bone bridge is created between the vertebrae, either pos-
terior, interbody or both. Originally, bone grafts were used
to promote interbody fusion. However, several complica-
tions were associated with the use of grafts. These include
donor site morbidity, a decrease in the intervertebral disc
space height due to graft collapse, graft subsidence, graft
retropulsion, graft resorption, fusion failure with subse-
quent pseudarthrosis and prolonged healing time [6,7].
As an alternative for bone grafts, interbody cages were
developed [7]. They are designed to be filled with bone,
allowing bony fusion through the cage to the adjacent ver-
tebrae. Both material and design of the cage play an import-
ant role in correcting spinal deformities and creating an
optimal environment for spinal fusion [8-10]. The develop-
ment of a solid bony fusion is influenced by mechanical
and biological factors. For example, the size and geometry
of the cage determines the initial mechanical stability
[11,12]. Furthermore cage stiffness is an important factor in
stress shielding [13,14]. Biological factors, such as the
osteointegration of the surface of the cage, influence qual-
ity, speed and attachment of newly formed bone [8].
Cages allow for direct axial load bearing and restore of
height of the intervertebral and foraminal space. Initially,
interbody cages were implanted in pairs via the trad-
itional posterior lumbar interbody fusion (PLIF) tech-
nique. More recently, a larger single oblique cage is used
that provides more stability [15,16].
Polyetheretherketone (PEEK) materials were used in
aerospace and aviation industries before researchers began
exploring them in medical devices, mainly in trauma and
femoral components of hip prosthesis [17,18]. Besides be-
ing radiolucent, PEEK is relatively inert and does not pro-
voke a strong foreign body reaction in vivo [19]. During
the late 1990’s the first PEEK cages for spinal fusion be-
came available. High fusion rates and good to excellent
clinical outcomes have been reported compared to titan-
ium cages and bone grafts [20,21]. Most spine surgeons
therefore prefer PEEK cages over other cages.To allow some visualization on radiograms and CT,
radio-opaque markers are present in PEEK cages. The
major advantage of PEEK cages over the metal cages is that
they produce less artifacts on CT or MR scans. However, a
radiolucent cage could also contribute to the difficulty of
radiographic assessment of its exact position in the spine.
For example, placement of the cage during surgery is less
accurate, and follow-up imaging is more difficult. This is
important to determine the cause of ongoing symptoms
and/or to determine if fusion has occurred. Additional
problems observed include a 14.3% rate of subsidence in
patients with PEEK cages after lumbar interbody fusion
[22]. Furthermore, posterior migration of a component of a
PEEK cage has been reported [23]. It has also been reported
that PEEK cages are generally encapsulated by a thin fi-
brous tissue layer rather than bone growing in intimate
contact with the polymer [24].
Better osteointegration of the cage is believed to
minimize the rate of subsidence and migration. There-
fore, researchers have been working on materials that
mimic the mineral content of bone for many years [25].
Ceramic implants can be manufactured with a rough
surface and have the potential to show a better integra-
tion with the host bone, which facilitates the attachment
of bone to the implant rather than the fibrous encapsu-
lation [24]. Ceramics are strong and light-weight and
have desirable imaging properties, free from artifacts on
CT and MRI [26].
Silicon nitride (Si3N4) is a ceramic with a compression
strength exceeding the usual plastic and metal materials
used for interbody cages. Unlike many other ceramics, sili-
con nitride resists brittle fractures; its toughness exceeds
that of alumina, a material with 30+ years of use in joint
replacements [27]. Silicon nitride is also highly compatible
with standard imaging techniques. The material is free
from artifacts on radiogram, CT and MRI images [26].
Several studies have demonstrated its biocompatibility and
its mechanical and osteoconductive qualities in vitro
[28-32]. Furthermore, compared to PEEK and titanium,
silicon nitride has a decreased bacterial activity on its sur-
face [33,34]. Based on good results in vitro, silicon nitride
is used in the development of bearings that can improve
wear and longevity of knee and hip prosthesis [32].
A preliminary study with silicon nitride interbody
cages showed good clinical and radiological results in 2
patients 1 year after a transforaminal lumbar interbody
fusion procedure [35]. Sorrell et al. presented the results
of a 10 year clinical follow-up study [36]. In this study
30 patients underwent anterior interbody fusion of the
lumbar spine using silicon nitride cages. They found a
durable interbody fusion after 5 years (21 out of 22 pa-
tients) and after 10 years (16 out of 16 patients). Please
note there was a 47% loss of follow-up. Silicon nitride
materials received the CE Mark and FDA market
Table 1 Inclusion and exclusion criteria
Inclusion criteria • Male and female patients age 18–75 years
• Chronic low back pain unresponsive
to at least six months of conservative care
• MRI and standing x-ray evidence
of Pfirrmann Grade III or greater disc
• Degeneration and/or degenerative
or isthmic spondylolisthesis of Grade I or II
• Signed informed consent
Exclusion criteria • Osteoporosis
• Patients with prior failed fusion at the same level
• Degenerative scoliosis
• Degenerative spondylolisthesis greater than Grade II
• Pregnancy
• Psychiatric or mental disease
• Alcoholism (drinking more than 5 units per day)
• Active infection or prior infection at the surgical site
• Active cancer
• Insufficient language skills to complete questionnaires
• Participation in another study
• More than two symptomatic levels that need fusion
• Planned (e)migration abroad in the year after inclusion
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have been used in the US for over 3 years, with no ad-
verse events reported [32].
Compared to PEEK cages silicon nitride cages are ex-
pected to have lower complications rates and allow higher
fusion rates due to better biocompatible and osteoconduc-
tive qualities. The purpose of this study is to compare the
clinical outcomes and fusion rates of PEEK cages with sili-
con nitride cages in patients with symptomatic degenera-
tive lumbar disc disorders.
Methods/Design
In our study, PEEK and silicon nitride interbody cages
will be compared in the treatment of degenerative lum-
bar disc disorders. This non-inferiority study is designed
as a multi-center (two center) clinical observer and pa-
tient blind randomized controlled trial with 2 parallel
treatment groups. The multi-center design is needed in
order to collect enough patients for reasons of statistical
power. To minimize observer bias, both patients and clin-
ical observers will be blinded for treatment during follow-
up. Clinical observers will not analyze radiograms and CT
because the silicon nitride cages are clearly visible. The
follow-up is 2 years, in which patients will fill out several
questionnaires and are examined both clinically and
radiologically.
Patient selection
Participation in our study will be requested from patients
(18–75 years old) who visit the outpatient clinic in one of
the participating hospitals. Patients must present with a
history of chronic low back pain with or without leg pain
that did not respond to conservative treatment and disc
degeneration of Pfirrmann Grade III [37] or higher and/or
isthmic or degenerative spondylolisthesis of Grade I or II,
confirmed by MRI.
The treating physician will discuss this study with the
patient and if the patient fulfills all inclusion criteria
(Table 1), the information form and informed consent
form is handed out to the patient. The patient can read
subsequently at leisure at home.
Patients who decide to participate in our study are
scheduled for an appointment with the researcher at the
outpatient clinic of the hospital. During this visit, the pa-
tient is extensively informed about the backgrounds, the
objectives, the investigational design and the assess-
ments of the investigation and the possible advantages
and disadvantages of the investigation. All this informa-
tion provided by the researcher matches the earlier pro-
vided patient information form. The patient is requested
to sign the informed consent. Pre-operative baseline data
will then be collected for the outcome scores as well as
patient’s demography. A neurological examination is per-
formed, the MRI and other tests are reviewed and thesurgery is discussed. All patients preoperatively visit an
anesthesiologist for standard medical assessment. All pa-
tients will be operated under general anesthesia.Randomization
Patients who meet the inclusion and exclusion criteria,
and have given informed consent are allocated the next
available investigational number (Patient ID number) and
will be randomly allocated to one of two groups (treat-
ment A or treatment B) by use of a centralized 24-hour
computerized randomization system that allows internet
randomization (Sealed Envelope Ltd. London). After com-
pleting follow-up at 2 years post-surgery both patient and
researcher will be informed which cage was used.Surgical management
Patients will undergo a transforaminal lumbar interbody
fusion with an oblique single PEEK or SiN cage (Amedica
Corporation, Salt lake City, Utah) supplemented by ped-
icle screw fixation, as described by Harms et al. [38]. De-
sign of the PEEK cage is similar to the SiN cage. Autograft
bone extracted from locally excised bone from the lumbar
spine will be used for cage filling. After surgery, patients
will be admitted for 3–4 days. Patients are encouraged to
mobilize as soon as possible. A lumbar support orthosis is
not prescribed.
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Several validated questionnaires described below will be
used for outcome assessments. During intake, a basic
physical exam with neurological examination (muscle
strength, reflexes) and additional assessments as re-
quired per normal practice will be performed to ensure
that the patient can undergo surgery safely. During
follow-up visits at 3, 6, 12 and 24 months the neuro-
logical examination will be repeated. See Table 2 for the
patient follow-up chart.
Primary outcome measure
Primary outcome will be measured by the Roland Morris
Disability Questionnaire (RMDQ). The 24 point RMDQ is
a widely used patient-completed measure of health out-
come for low back pain [39-41]. The patient will complete
the Dutch version of the questionnaire, which is validated
for the Dutch population [42], and the sum of the scores
will be used to measure disability. The score ranges from
0 to 24, with a higher score indicating more severe disabil-
ity. Primary objective is to measure the average improve-
ment in RMDQ for the silicon nitride patients versus
those that receive similar-shaped PEEK cages.
Secondary outcome measures
SF-36: The SF-36 will be used as the generic quality of
life questionnaire [43,44]. The SF-36 questionnaire has
been applied and validated numerous times for inter-
vention studies with back pain and spine surgery. The




















Complications Xfunctional status of patients. The questions are divided
in eight domains:
 Physical functioning
 Physical role limitations
 Emotional role limitations
 Social functioning
 Physical pain
 General mental health
 Vitality
 General health perception
Each domain is converted to a 0 to 100 score, a higher
score indicating a better health condition. The eight do-
mains are also combined into a physical and psycho-
logical summary score. These are converted to range
from 0 to 100 with an average person at 50 and a stand-
ard deviation of 10 points.
Pain (Back and Leg VAS): The pain intensity in the
back and legs are rated by the patient on a 100 mm
horizontal visual analog scale (VAS). The two ends
of the scale are “no pain” at 0 mm and “the most
terrible pain I can imagine” at 100 mm. The patient
is asked to mark the scale based on the average pain
intensity during the week prior to the visit to the
outpatient clinic. During each visit, the patient will
complete one VAS for the pain in either leg, and
one VAS for back pain.
Likert score: Recovery is rated by the patient on a 7-
point Likert score in which 1 defines complete recovery3 months 6 months 12 months 24 months
3 4 5 6
X X X X
X X X X
X X X X
X X X X
X
X X X X
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in good recovery (‘complete recovery’ and ‘almost complete
recovery’) and bad recovery (‘little recovery’ to ‘worse than
ever’). Patient will complete the Likert score at the day of
discharge from the hospital and during each follow-up
visit.
Radiographic Images (Plane radiogram, MRI, CT): A
pre-operative MR and a set of standing plane radiograms
of the lumbar spine will be collected for all patients. Pre-
operative disc degeneration will be evaluated on the MR
scan by the method of Pfirrmann [37]. Patient fusion sta-
tus will be evaluated according to the criteria mentioned
by Burkus et al. which are based on qualitative observa-
tions [45,46]. Determination of fusion involves the radio-
graphic evaluation of angular changes in spinal alignment,
assessment of the device-host interface, and identification
of new bone formation and bone remodeling [46]. Anter-
ior – posterior radiograms will be collected after 3, 6, 12
and 24 month. After one year, a CT scan (Siemens sensa-
tion 16, 3.0 mm slice) of the lumbar spine will be collected
to monitor new bone formation and bone remodeling
within and around the central core of the cages. Two radi-
ologists will independently analyze the lumbar radiograms
and CT. Disagreement between the radiologists will be re-
solved by consensus.
Complications, adverse events, additional surgery
The investigators will record all complications and adverse
events accurately. These will be grouped in the following
categories:
 Infections, grouped as superficial wound infections
and deep wound infections
 Post-surgical hematoma
 Increased neurological symptoms
 Venous thrombosis
 Other (serious) adverse events
All adverse events and complications will be moni-
tored and followed up until stable or resolved during the
course of the study. Each adverse event will be reported
to the operating surgeon and will be associated to the
type of cage used to qualify the event to be related. Code
breaking will occur by the clinical observer or operating
surgeon if the clinical condition of the patient necessi-
tates this. Early termination of the study will be decided
if necessary.Additional surgery
All additional surgeries during the follow-up period that
are related to surgery will be recorded. Any additional
spine surgery at the operated level will be considered as
a complication and a poor result.Withdrawal of participants from the trial
A participant may be withdrawn from the clinical study
for the following reasons:
 Patients may choose to withdraw from the study
under the terms of the Declaration of Helsinki and
their consent documentation without having to give
a reason
 Any unanticipated adverse reaction which is, in the
opinion of the researcher, related to the treatment
and will endanger the well-being of the patient if
treatment is continued
 The development of any intercurrent illness(es),
infection or condition(s) that might interfere with
the clinical investigation
 Non-compliance with the study procedures deemed
by the investigator to be sufficient to cause
discontinuation
 Any problem deemed by the Investigator to be
sufficient to cause discontinuation
All patients discontinued from the investigation due to
an unanticipated adverse reaction, directly related to the in-
vestigation, will be treated until the reaction resolves. The
researcher will clearly document the date and reason(s) for
the patient withdrawal. Patients who have withdrawn from
the study will not be replaced if they have received investi-
gation treatment. If possible, any procedures or assessments
planned for the patient on withdrawal from the investiga-
tion should be performed when intention to withdraw the
patient is announced. Patients who are withdrawn prior to
receiving treatment will be replaced.Data management
All data recorded during intake, hospitalization and
follow-up visits will be de-identified. Participants will be
identified by a unique investigational number (Patient ID
number) allocated during intake. Primary and secondary
outcome variables, information gathered during intake
and hospitalization and all complications, additional sur-
gery, adverse events and withdrawals will be entered by the
researcher into an electronic data capture system (Acumen
Healthcare Solutions, LLC, Plymouth, Minnesota, USA).
The source documents will be stored in the hospital where
the patient underwent the surgical procedure and shall be
retained for a period of minimal 5 years after the study
completion or longer if deemed necessary.Statistical considerations
Sample size
The sample size calculation is based on the primary object-
ive to compare the silicon nitride and PEEK cages with re-
spect to improvement in RMDQ score and to demonstrate
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cage.
In a large spinal fusion cohort study, Robertson [47]
found a mean RMDQ improvement of about 10 points.
Scheufler also noted an improvement from a pre-treatment
score of 17 to 7 at eight months post-op, with a standard
deviation of 4 [48]. Both studies included patients with
back pain from degenerative disc disease and degenera-
tive spondylolisthesis.
The maximal difference between the treatment arms
that could be considered potentially no longer clinically
relevant for the RMDQ is thus a difference in improve-
ment of 2–3.5 points [39,41,49]. We therefore consider a
non-inferiority margin of 2.6 points between the treat-
ment arms to reflect the maximal difference that is not
clinically relevant. Non-inferiority is to be demonstrated
based on a one-sided confidence interval with signifi-
cance level of 2.5% for the difference between the two
treatment arms. Assuming a standard deviation of 4
points, 50 patients per arm provide 90% power to dem-
onstrate non-inferiority within a non-inferiority margin
of 2.6 points. The total of 100 patients shall be random-
ized into two groups to minimize bias. This sample size
is based on comparing treatment groups with a t-test.
The actual analysis is a repeated measurements analysis
with baseline as covariate, which is more efficient (re-
quiring less patients, at least about 10% if the correlation
between baseline and endpoint is 0.3). Thus, no add-
itional sample size increase is incorporated to account
for drop-out. Sensitivity analyses to assess impact of
drop outs will be performed.
Statistical analysis
The primary analysis will be on the change from baseline
in RMDQ score. This will be analyzed based on a mixed
model for repeated measurements, including baseline
RMDQ as covariate and treatment and center as factors.
No imputation will be applied for this analysis. The pri-
mary comparison will be at 12 months of follow-up.
Sensitivity analyses to assess impact of drop outs will
be performed. These will include an analysis based on
Last Observation Carried Forward imputation, as well as
multiple imputations based on differential patterns of
drop out/missing data reasons.
An exploratory analysis of the distribution of the indi-
vidual improvements in change from baseline in RMDQ
score versus the fusion rate (in three categories) within
treatment groups will be performed to assess the extent
to which both are consistent.
Other continuous outcomes assessed at each visit will
be analyzed similarly. Dichotomous outcomes will be
compared between treatment groups based on Z-tests for
comparing proportions, with results expressed as 95%
confidence intervals for the difference in proportions.Ethical considerations
This study is designed in concordance with the declar-
ation of Helsinki. The protocol has been reviewed and ap-
proved by the local medical ethical committee (Verenigde
Commissies Mensgebonden Onderzoek). The general board
of the participating hospitals also agreed with the
protocol. Informed consent will be obtained before par-
ticipation in this study. Patients are informed they are
free to refuse participation. If they choose to participate
they may withdraw from this study at any time without
comprising further medical care. No financial rewards
will be present for patients who agree to participate.
Discussion
PEEK cages are widely used in the treatment of lumbar
degenerative disc disorders, and show good clinical results
[20,21]. Nevertheless, complications such as subsidence
and migration of the cage are frequently seen [22,23]. A
lack of osteointegration and fibrous tissues encapsulating
PEEK cages are held responsible [24]. Ceramic implants
made of silicon nitride show better biocompatible and
osteoconductive qualities [28-34]. Therefore it is expected
that the use of silicon nitride cages decrease such compli-
cations by better fusion rates. A study design of a double
blind multi-center randomized controlled trial is presented
in this article, in which PEEK cages will be compared with
silicon nitride cages in the treatment of symptomatic de-
generative lumbar disc disorders. Primary objective is to
show that treatment with the silicon nitride cage produces
similar improvement in RMDQ at all follow-up times com-
pared to the PEEK cage. Total follow-up is 2 years. To our
knowledge, this is the first randomized controlled trial in
which the silicon nitride cage is compared with the PEEK
cage in patients with symptomatic degenerative lumbar disc
disorders.
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